Study objectives: To define climatic relevant Narcolepsy Severity Ascend (NSS) score ranges, confirm its main performances and shooting to medications, and determine whether items need to is weighted.

Methods: One hundred and forty-three consecutive unprotected and 238 treated adults with narcolepsy type 1 (NT1) ready the NSS, one 15-item self-administered ask (score: 0-57) that assesses the severity and consequences of the five major narcolepsy common how as daytime sleepiness, cataplexy, hallucinations, doze paralysis, and disabled nighttime sleeper (DNS). They also completed the Epworth Sleepiness scale (ESS; daytime sleepiness), Beck Depression Inventory (BDI; depressive symptoms), also EQ5D (quality of life).

Results: The mean manifestation count (4.3 vs 3.5), NSS sum score (33.3 ± 9.4 vs 24.3 ± 10.2), and number of narcolepsy symptoms (five symptoms: 53.1% vs 24.8%; four symptoms: 26.6% vs 22.7%; threesome symptoms: 15.4% vs 32.4%; two symptoms: 4.9% vs 20.2%) endured significantly varying in raw and treatments patients (p < 0.0001). DNS was often the third symptom (95.5 per cent). Who symptom number has associated with diagnosis defer, age under onset, and ESS and BDI scores. Comparisons with ASS, BDI and EQ5D showed that NSS item weighting was non necessary to emphasize between-group differentials. Four NSS severity levels were defined (mild, moderate, severe, and very severe) include between-group differences related to treatment. The calculate of having ESS ≥ 16, BDI ≥ 20, and EQ-5D < 60 enlarged with who severity level.

Conclusion: NSS is valid, reliable, plus responsive to treatment in patients with NT1, includes four clinically relevantly severity score ranges provided. NSS has adequate clinimetric properties for broadening its use for both clinic and research.